Who We Are

Steve Bradshaw

BSc (Hons.), MB BChir, MRCOphth

Managing Director

Steve Bradshaw is Founder and Managing Director of award winning global market access consultancy – Valid Insight. He has two decades’ experience in market access consulting and healthcare. He has developed price and access strategies and value communication tools for many well-known products on the market, and has supported numerous companies on many aspects of market access, pricing, tendering, contracting, value communication and operational excellence.

Steve’s career includes being Editor at Nature Clinical Reviews, Ophthalmic Surgeon UK National Health Service, and various positions to senior executive level in market access consulting firms including United BioSource Corporation, Evidera and Market Access Solutions LLC, prior to launching Valid Insight. His education includes a first-class BSc in Biochemistry, degrees in Medicine and Surgery from Gonville and Caius College, Cambridge, and a postgraduate diploma in Ophthalmology.

Steve writes and speaks regularly on the challenges facing the global healthcare environment; he presents widely at conferences and expert panels, and has authored over 30 publications. His research interests span multiple therapy areas across drugs, devices and biotechnologies, including innovative medicines for rare diseases. He is a peer reviewer for several medical journals, Editorial Board Member for the journal Medicine Access @ Point of Care, Advisory Board Member at Pharma-IQ and the Global Pneumonia Prevention Coalition, and has been quoted in publications such as BioPharm Insight, Hospital Pharmacy Europe, and Reuters.

Raf De Wilde

PhD

Senior Executive Advisor

Raf De Wilde is Senior Executive Advisor at Valid Insight. He is a global expert in life science market access, having over 39 years’ experience in the pharmaceutical industry and over 29 years in global market access.

Raf became the head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998.

In 1997, he joined Peter Lauper’s team that pioneered the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a centre of excellence for oncology pricing and specialised in biologics while leading the HEOR function at CENTOCOR. Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products from 2004 to 2010.

Raf joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015, prior to joining Valid Insight in 2016. In his consulting career he has led nearly 200 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 150 training workshops in Asia, Asia-Pacific, Europe, North America and Middle-East, and led the life sciences pricing training of the European Pricing Platform from 2011 to 2014.

Raf continues to teach the sessions on PROs and evidence-based medicine at the Master of Science in Pharmaceutical Medicine course of the University of Duisburg-Essen in Germany.

Crispin Jenkinson
BA, MA, MSc, DPhil

Senior Advisor

Crispin Jenkinson is Senior Advisor at Valid Insight. He is Professor of Health Services Research, Director of the Health Services Research Unit at the Nuffield Department of Population Health, and a Senior Research Fellow of Harris Manchester College at the University of Oxford. He graduated from Bedford College (University of London) before coming to Oxford where he gained an MSc in Psychology and then undertook research on the psychological impact of long-term illness for a DPhil. His main research interests include patient reported outcomes (PROs) and health status measurement, the evaluation of patient experiences of medical care, and methodology. He has extensive experience of developing and validating outcome measures and, in collaboration with others, has conducted randomised controlled trials in which such instruments have been primary end-points. This work has led to the development of several internationally recognized PRO measures including the Parkinson’s Disease Questionnaire (PDQ), Amyotrophic Lateral Sclerosis Questionnaire (ALSAQ), and the Endometriosis Health Profile (EHP). He has written and edited many books as well as having authored over 230 peer reviewed publications.

Crispin helps our clients develop fit-for-purpose PRO and other health status instruments.

Carole Alison Chrvala
MA, PhD

Senior Advisor

Carole Chrvala is Senior Advisor at Valid Insight. She has nearly 30 years’ experience as an epidemiologist and HEOR researcher. Her work spans collaborations with government health agencies, payers, academic institutions, pharmaceutical and medical device companies, medical education and communication organisations, and healthcare professional societies located in the US, UK, EU, and Israel. Carole is highly experienced in epidemiologic consulting, biostatistical support, strategic competitive analysis, medical intelligence, medical writing and publication planning services in diverse therapeutic areas including oncology, cardiovascular disease, diabetes mellitus, infectious diseases, musculoskeletal disorders, neurologic disorders, pain, psychiatric disorders, rare diseases, respiratory disorders, rheumatologic disorders, and women’s health.

Carole has developed and validated risk prediction models for various chronic and infectious diseases, analysed health care resource utilisation and economic burden, determined projections for the global epidemiologic burden of diverse health conditions, developed prospective and retrospective research studies to examine the impact of clinical interventions and developed statistical analysis plans for retrospective and prospective case-control studies and randomised clinical trials.

Carole was director of Cancer Prevention and Control for the Colorado Department of Public Health and Environment (CDPHE), before setting up her own independent company. She joined the US Food and Drug Administration as a Senior Scientist and later joined the National Academies of Science as a Senior Program Officer. She has written and presented on epidemiology, health economics and outcomes research, and diverse health topics to more than 75 professional audiences and organisations.

Carolyn Steeds
BSc (Hons), PGCert Health Economics

Associate Director – Value Comms

Carolyn has 30 years’ experience in the healthcare industry, comprising 15 years in pharmaceuticals, 13 years in consultancy and 3 years in diagnostics. Over 20 years of this time has been spent working in HEOR and Market Access where Carolyn gained considerable experience in developing: value dossiers and key value messages, market access strategies, value communication tools, health economic data to support pricing and reimbursement and outcomes research studies.

Carolyn worked for many years in consultancy as an independent consultant in the area of HEOR and value communications, and for several years in market access consultancy. Carolyn has managed numerous projects working with large global pharmaceutical companies to smaller diagnostic manufacturers delivering high quality deliverables across a wide range of therapy areas including; oncology, infectious diseases, neurology, ophthalmology, medical devices (insulin pumps, gastric bands) and in-vitro Diagnostics (biomarker testing for cancer, molecular assays for infection).

Carolyn has an honours degree in Biology from Strathclyde University and a postgraduate certificate in Health Economics from Aberdeen University.

Sam Davies
BSc (Hons)

Lead Consultant

Sam specialises in the delivery of payer-focussed market access materials such as value dossiers, value propositions and objection handlers which help clients demonstrate the value of their brands.

Sam started his professional career in the National Horizon Scanning Centre (NHSC) at the University of Birmingham. The NHSC was a public body funded by UK National Institute for Health Research (NIHR) ) to provide key NHS decision makers with advance notice of new and emerging health technologies that may have a significant impact on patients and/or service delivery or costs.

Sam has also worked for several years in the payer communications division of Evidera developing a range of market access materials. He managed numerous projects working with large global pharmaceutical companies and small single-product biopharma companies delivering high quality deliverables across a wide range of therapy areas, including orphan diseases.

Most recently Sam has worked in the UK and Ireland affiliate of Eli Lilly and Gilead Sciences, working on launch, established and legacy brands across therapy areas including immunology, HIV and oncology/cell therapy.

Sam has a first class honors degree in Biomedical Science from the University of Birmingham.

Jordy Van Enkhuizen
PharmD, PhD

Consultant

Jordy van Enkhuizen is a Consultant at Valid Insight with extensive experience in the healthcare industry. Prior to joining Valid Insight, he gained experience in value communications at Evidera and ICON. Jordy also worked as a hospital pharmacist in the Netherlands, dealing with a broad range of therapeutic areas and being involved in decision-making processes required for administration of high cost treatments. In between, he worked with the NGO Médecins Sans Frontières and supervised all aspects of two pharmacies in the Democratic Republic of Congo.

He has extensive experience in value proposition and message development, Global and European core value dossiers and the creation of tools and communication materials that drive effective payer engagement. Other areas of expertise include objection handlers, internal training sessions for roll out of value communication deliverables and various other global market access materials.

Jordy has authored over 15 publications in peer-reviewed scientific journals and presented at international conferences. He is fluent in Dutch, English and speaks French and Spanish. Jordy has a BSc and MSc in pharmaceutical sciences from the University of Utrecht and a PhD in behavioural pharmacology from the University of California San Diego.

Ejike Nwokoro
MD, MPH

Associate Consultant

Ejike Nwokoro joined Valid Insight. Prior to that he worked at Cogora Ltd as a Senior Insight & Market Access Analyst focusing primarily on Payer and KOL engagement. Before Cogora he worked as an Advisor on Global Pharmaceutical Policy at the Norwegian Institute of Public health, and as a Researcher with the Oslo Group on Global Health Policy (University of Oslo, Norway) with specific interests in Health Technology Assessment(HTA) models and global collective action for health system strengthening.

Other Market Access related experience includes: Prescribing data analysis; Advisory boards for development and pressure testing of value strategies and assessment of new contracting models for product manufacturers; Payer research to support market entry and product positioning, and key customer identification projects to support launch and salesforce planning.

Ejike has been part of a multinational research project sponsored by the European Commission and the European Pharmaceutical Industry Association (EFPIA) focusing on economic models that incentivise reinvestment in R&D while advocating responsible antibiotics use. At the University of Bergen, he led a research project that sought to identify future options with respect to funding mechanisms for Global Public Goods for Health. Ejike is a medical doctor by background and has a master’s degree in Public Health from the University of Wolverhampton, UK as well as Postgraduate Education in Health Economics, Quality Improvement and Healthcare Management from the University of Bergen, Norway. He is fluent in Norwegian and English.